Ethylone (β-keto-MDEA, bk-MDEA, 3,4-methylenedioxy-N-ethylcathinone) is a synthetic entactogen and stimulant of the cathinone chemical class, structurally derived from MDEA (MDE, "Eve") — the N-ethyl analog of MDMA — through the addition of a beta-ketone group to the alpha carbon. It belongs to the MDxx cathinone family alongside methylone, butylone, and mephedrone, sharing their dual stimulant and entactogenic character.
Ethylone acts as a mixed reuptake inhibitor and releasing agent for serotonin, dopamine, and norepinephrine, mirroring the general mechanism of MDMA but with a characteristically different balance: ethylone has a higher dopamine-to-serotonin activity ratio than MDMA, producing effects that are more prominently stimulant and less empathogenic. Users describe a combination of energy, euphoria, mild mood lift, and some emotional openness — positioned closer to a cathinone stimulant than to pure MDMA, while retaining more entactogenic qualities than non-methylenedioxy cathinones.
The duration of ethylone is typically 2–4 hours when taken orally — shorter than MDMA (3–5 hours) — and the overall intensity is generally reported as milder. The post-use period involves some serotonergic depletion-related comedown effects (low mood, fatigue), though these are usually less pronounced than post-MDMA.
As a cathinone analog of MDEA, ethylone carries the full spectrum of MDxx cathinone risks: serotonin syndrome in combination with MAOI agents, cardiovascular stimulation, potential serotonergic neurotoxicity with repeated heavy use, and the general cathinone-class compulsive redosing tendency. Harm reduction approaches for MDMA provide the closest applicable framework, with appropriate adjustments for cathinone-specific characteristics.
Safety at a Glance
High Risk- Distinguish from MDMA
- Marquis reagent: MDMA produces purple-black; ethylone produces orange-brown — a clear distinction
- Toxicity: Serotonin Syndrome Risk Ethylone's serotonergic activity creates genuine serotonin syndrome risk in combination with ...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: Stimulant overdose from Ethylone is a medical emergency primarily involving cardiovascular and ne...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 2 hrs – 4 hrsHow It Feels
Ethylone introduces itself as a gentler, more restrained cousin of MDMA. Within thirty to sixty minutes of oral ingestion, a warmth begins to build in the chest. It is not the dramatic wave that characterizes methylone or MDMA, but a gradual, spreading glow that softens the edges of social anxiety and replaces it with a mild but genuine openness. Colors may appear slightly more vivid, and music takes on a richer, more emotionally resonant quality. The body relaxes into a comfortable state of mild stimulation, alert but not driven.
At the peak, which arrives around one to two hours in, ethylone occupies an interesting middle ground between stimulant and empathogen. There is a definite increase in sociability and emotional warmth, a desire to connect with others that goes beyond ordinary extroversion. Touch feels pleasant, conversations feel meaningful, and there is a sense of goodwill toward the people in one's immediate environment. However, these effects are muted compared to full-strength empathogens. The empathy is present but not overwhelming, the euphoria real but not transcendent. The mind remains clear and functional, capable of navigating complex social situations without the serotonergic haze that can make more potent empathogens feel disorienting.
Physically, the effects are mild. Heart rate increases modestly, jaw tension is present but manageable, and appetite is suppressed. There is a gentle energy that encourages movement and social engagement without the compulsive need to pace or fidget. Body temperature rises slightly, and mild sweating is possible during physical activity. The overall physical profile is tolerable and unremarkable, unlikely to cause significant discomfort at moderate doses.
The experience tapers over three to five hours, fading gently into a state of quiet contentment before baseline reasserts itself. The comedown is notably less severe than MDMA or methylone, producing only a mild tiredness and a slight emotional flatness that resolves quickly. Some users report a brief afterglow of elevated mood and social warmth the following day. The most common assessment of ethylone is that it is pleasant but underwhelming, offering a taste of the empathogenic experience without its full depth. For some, this moderation is precisely the point; for others, it merely highlights what is missing.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(15)
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
- Vibrating vision— Vibrating vision is the subjective experience of the visual field rapidly oscillating or shaking due...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Cognitive(13)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
Ethylone acts as a mixed monoamine reuptake inhibitor and releasing agent. It targets all three primary monoamine transporters:
- SERT (serotonin): Entactogenic, empathogenic component
- DAT (dopamine): Euphoric, rewarding, stimulant component
- NET (norepinephrine): Cardiovascular stimulation, arousal, alertness
The DAT:SERT selectivity ratio of ethylone is believed to be higher (more dopaminergic) than MDMA, accounting for the more stimulant-like character of the experience. The methylenedioxy ring — shared with MDMA and other MDxx cathinones — contributes to the serotonergic activity responsible for the entactogenic qualities.
Beta-Ketone Modification
Like all cathinones, the presence of a beta-ketone group at the alpha carbon of the phenethylamine backbone reduces lipophilicity compared to the parent phenethylamine (MDEA). This reduces blood-brain barrier penetration and is believed to contribute to the generally lower potency and shorter duration of cathinones compared to their non-cathinone counterparts.
Pharmacokinetics
Ethylone is typically active at oral doses of 100–250 mg. Onset begins at 30–60 minutes and primary effects last 2–4 hours. The shorter duration than MDMA reflects both the beta-ketone pharmacokinetic modification and potentially different metabolic pathways.
Comparison with Methylone and Butylone
Ethylone's N-ethyl group (versus N-methyl in methylone) modestly shifts the pharmacological profile and affects the compound's transporter binding affinity pattern. The structural difference results in a somewhat different character — though both are MDxx cathinones with broadly similar profiles, the specific SERT:DAT balance differs.
Detection Methods
Standard Drug Panel Inclusion
Ethylone is a substituted cathinone (synthetic cathinone) that is not included on standard 5-panel or 10-panel immunoassay drug screens. Some extended panels (particularly those marketed for "bath salts" detection) may include cross-reactive antibodies for the cathinone class, but coverage is inconsistent. The structural relationship to amphetamine means some cathinones trigger the amphetamine channel on immunoassays, but this is compound-specific and unreliable for Ethylone.
Urine Detection
Ethylone and its metabolites can typically be detected in urine for 2 to 4 days following a single dose. Repeated or binge-pattern use may extend this window to 5 or more days. Primary metabolic pathways involve reduction of the beta-keto group, N-dealkylation, and hydroxylation. The resulting metabolites are excreted renally, often as glucuronide or sulfate conjugates.
Blood and Saliva Detection
Blood detection windows for Ethylone range from 12 to 48 hours depending on dose and individual metabolism. Plasma concentrations decline rapidly due to extensive distribution into tissues. Oral fluid testing can detect Ethylone for approximately 24 to 48 hours but is not commonly deployed for synthetic cathinones outside of specialized forensic settings.
Hair Follicle Detection
Hair analysis can detect synthetic cathinones including Ethylone for up to 90 days. Incorporation into the hair shaft follows standard pharmacokinetic principles for basic amines. However, most commercial hair testing panels do not specifically target Ethylone, requiring custom LC-MS/MS methods with appropriate reference standards.
Confirmatory Testing
Definitive identification of Ethylone requires instrumental analysis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for synthetic cathinones due to their thermal lability, which can cause degradation during gas chromatography. GC-MS remains usable but may require derivatization for optimal sensitivity. Reference standards specific to Ethylone are necessary for quantitative confirmation.
Reagent Testing
Marquis reagent typically produces no reaction or a faint yellow-orange color with Ethylone. Mecke reagent may show no significant color change. Mandelin reagent can produce a yellow to brown reaction. The lack of strong, characteristic color reactions with common reagents makes cathinone identification by reagent testing alone unreliable. A combination of Marquis, Mecke, Mandelin, and Simon's reagents can help rule out other substance classes but cannot positively confirm Ethylone.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Chemical Origins
Ethylone was first synthesized by Alexander Shulgin and documented in his PiHKAL: A Chemical Love Story (1991) alongside a comprehensive characterization of its pharmacological and subjective properties. Shulgin described the compound as an entactogen with MDMA-like but distinct qualities.
Emergence in NPS Markets
Ethylone emerged in the designer drug market in the late 2000s and early 2010s alongside methylone and butylone. It was identified in forensic analyses of "bath salts" and research chemical products across Europe, North America, and Australia. It appeared both as a named product and as an adulterant in products sold as MDMA.
Regulatory History
Ethylone was placed under regulatory control in the United States via emergency scheduling in 2012 and permanently scheduled in 2014. Similar controls were implemented across the EU, UK, Australia, and other jurisdictions. The UK Psychoactive Substances Act 2016 effectively prohibited the entire class.
Public Health Context
Ethylone was identified in toxicological analyses associated with adverse events and was part of the broader public health response to the MDxx cathinone NPS wave. It appeared in combination with other cathinones in mixed-drug presentations, contributing to the complex harm landscape of the NPS era.
Harm Reduction
Distinguish from MDMA
Ethylone cannot be distinguished from MDMA by appearance. This is a critical harm reduction issue — many users have taken ethylone believing it was MDMA, with significant differences in expected dose, duration, and character:
- Marquis reagent: MDMA produces purple-black; ethylone produces orange-brown — a clear distinction
- Always test before use
Dose Carefully and Account for Potency Differences
Ethylone requires higher doses than MDMA for equivalent effects due to lower potency. Do not assume MDMA dosing norms translate directly:
- Start with a modest dose (100–150 mg for ethylone vs. 80–120 mg for MDMA)
- Wait 90 minutes for full onset before reassessing
Space Use Adequately
The serotonergic component means recovery time between sessions is essential:
- A minimum of 4–8 weeks between sessions is advisable
- More frequent use increases neurotoxic risk and degrades the quality of subsequent experiences
Avoid MAOI Combination
This is an absolutely contraindicated combination — do not combine ethylone with any MAOI under any circumstances.
Manage the Comedown
Post-ethylone effects (low mood, fatigue) are manageable but real:
- Ensure adequate sleep following use
- Allow 1–2 days of recovery time
- Avoid using additional drugs to manage the comedown
Toxicity & Safety
Serotonin Syndrome Risk
Ethylone's serotonergic activity creates genuine serotonin syndrome risk in combination with monoamine oxidase inhibitors (MAOIs). This is the highest-priority toxicity concern for ethylone, as serotonin syndrome can be life-threatening. The combination is absolutely contraindicated.
Cardiovascular Effects
Elevated heart rate, blood pressure increase, and peripheral vasoconstriction occur via norepinephrine and dopamine reuptake inhibition. While generally less severe than with high-potency pyrrolidine cathinones, these effects are meaningful and represent real risk for people with cardiovascular disease or hypertension.
Neurotoxicity Risk
MDMA produces serotonergic neurotoxicity with heavy, repeated use — specifically, damage to serotonergic nerve terminals. MDxx cathinones like ethylone share a mechanistic basis for similar toxicity. While ethylone-specific neurotoxicity data in humans is extremely limited, the prudent assumption is that heavy, frequent use carries similar risk to MDMA.
Comedown and Serotonin Depletion
The post-use serotonin depletion that follows MDxx cathinone use produces a comedown period of variable intensity: low mood, fatigue, reduced emotional responsiveness, and sleep disruption. These effects are generally milder than post-MDMA comedowns but are real.
Drug Interactions
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from Ethylone is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Brazil: Ethylone is illegal to possess, produce, and sell under Portaria SVS/MS nº 344.
China: As of October 2015, Ethylone is a controlled substance in China.
Germany: Ethylone is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Sweden: Ethylone is a controlled substance since 1992
Switzerland: Ethylone is a controlled substance specifically named under Verzeichnis D.
United Kingdom: Ethylone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.
United States: Ethylone is unscheduled in the United States. However it could be considered an analog of methylone or MDMA, thus putting it under the scope of the Federal Analog Act.
Responsible use
Research chemical
Substituted cathinone
Stimulants
Methylone
Ethylone (Wikipedia)
bk-MDEA (Erowid Vault)
Ethylone (Isomer Design)
Discussion
Ethylone / BK-MDEA (Bluelight)
Experience Reports (1)
Tips (5)
Do not take Ethylone in the afternoon or evening if you want to sleep that night. Most stimulants have long half-lives and even if you feel you can sleep, the quality will be significantly impaired.
Weigh your dose of Ethylone with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
Do not combine Ethylone with MAOIs or other serotonergic drugs. Many stimulants have serotonergic activity, and combinations can cause serotonin syndrome or hypertensive crisis, both medical emergencies.
If you snort Ethylone, use a clean straw (never shared), crush the powder as finely as possible, alternate nostrils, and rinse with saline spray after your session. Chronic insufflation damages nasal tissue and septum.
Start low with Ethylone and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: Ethylone
PubChem compound page for Ethylone (CID: 57252245)
pubchem - Ethylone - TripSit Factsheet
TripSit factsheet for Ethylone
tripsit - Ethylone - Wikipedia
Wikipedia article on Ethylone
wikipedia